Literature DB >> 29915400

Office-Based Point of Care Testing (IgA/IgG-Deamidated Gliadin Peptide) for Celiac Disease.

Michelle S Lau1, Peter D Mooney1, William L White1, Michael A Rees1, Simon H Wong1, Marios Hadjivassiliou1, Peter H R Green1, Benjamin Lebwohl1, David S Sanders1.   

Abstract

OBJECTIVES: Celiac disease (CD) is common yet under-detected. A point of care test (POCT) may improve CD detection. We aimed to assess the diagnostic performance of an IgA/IgG-deamidated gliadin peptide (DGP)-based POCT for CD detection, patient acceptability, and inter-observer variability of the POCT results.
METHODS: From 2013-2017, we prospectively recruited patients referred to secondary care with gastrointestinal symptoms, anemia and/or weight loss (group 1); and patients with self-reported gluten sensitivity with unknown CD status (group 2). All patients had concurrent POCT, IgA-tissue transglutaminase (IgA-TTG), IgA-endomysial antibodies (IgA-EMA), total IgA levels, and duodenal biopsies. Five hundred patients completed acceptability questionnaires, and inter-observer variability of the POCT results was compared among five clinical staff for 400 cases.
RESULTS: Group 1: 1000 patients, 58.5% female, age 16-91, median age 57. Forty-one patients (4.1%) were diagnosed with CD. The sensitivities of the POCT, IgA-TTG, and IgA-EMA were 82.9, 78.1, and 70.7%; the specificities were 85.4, 96.3, and 99.8%. Group 2: 61 patients, 83% female; age 17-73, median age 35. The POCT had 100% sensitivity and negative predictive value in detecting CD in group 2. Most patients preferred the POCT to venepuncture (90.4% vs. 2.8%). There was good inter-observer agreement on the POCT results with a Fleiss Kappa coefficient of 0.895.
CONCLUSIONS: The POCT had comparable sensitivities to serology, and correctly identified all CD cases in a gluten sensitive cohort. However, its low specificity may increase unnecessary investigations. Despite its advantage of convenience and rapid results, it may not add significant value to case finding in an office-based setting.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29915400     DOI: 10.1038/s41395-018-0143-3

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Diagnostic Accuracy of a Point-of-Care Test for Celiac Disease Antibody Screening among Infertile Patients.

Authors:  Louise Grode; Thomas Møller Jensen; Tina Parkner; Inge Errebo Agerholm; Peter Humaidan; Bodil Hammer Bech; Cecilia Ramlau-Hansen
Journal:  Inflamm Intest Dis       Date:  2019-07-23

2.  Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts.

Authors:  Hugo A Penny; Suneil A Raju; Michelle S Lau; Lauren Js Marks; Elisabeth Mr Baggus; Julio C Bai; Gabrio Bassotti; Hetty J Bontkes; Antonio Carroccio; Mihai Danciu; Mohammad H Derakhshan; Arzu Ensari; Azita Ganji; Peter H R Green; Matt W Johnson; Sauid Ishaq; Benjamin Lebwohl; Adam Levene; Roxana Maxim; Hamid Mohaghegh Shalmani; Mohammad Rostami-Nejad; David Rowlands; Irene A Spiridon; Amitabh Srivastava; Umberto Volta; Vincenzo Villanacci; Graeme Wild; Simon S Cross; Kamran Rostami; David S Sanders
Journal:  Gut       Date:  2020-11-02       Impact factor: 23.059

Review 3.  Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy.

Authors:  Gaetana Paolella; Silvia Sposito; Antonio Massimiliano Romanelli; Ivana Caputo
Journal:  Int J Mol Sci       Date:  2022-07-06       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.